Eiichi Ogawa

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4828886/publications.pdf

Version: 2024-02-01

134 papers	3,069 citations	172207 29 h-index	182168 51 g-index
140 all docs	140 docs citations	140 times ranked	3682 citing authors

#	Article	IF	Citations
1	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. Clinical Gastroenterology and Hepatology, 2022, 20, 874-885.e4.	2.4	4
2	Longâ€term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by directâ€acting antivirals. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 190-199.	1.4	3
3	Onâ€treatment gammaâ€glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. Liver International, 2022, 42, 59-68.	1.9	10
4	Longâ€term hepatic function of patients with compensated cirrhosis following successful directâ€acting antiviral treatment for hepatitis C virus infection. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 371-377.	1.4	6
5	Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. Hepatology International, 2022, 16, 48-58.	1.9	7
6	Sequential HBV treatment with tenofovir alafenamide for patients with chronic hepatitis B: week 96 results from a real-world, multicenter cohort study. Hepatology International, 2022, 16, 282-293.	1.9	5
7	Editorial: the role for PIVKAâ€II measurement after HCV elimination by directâ€acting antiâ€virals in terms of prediction of hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2022, 55, 122-123.	1.9	1
8	A case of severe COVID-19 with pulmonary thromboembolism related to heparin-induced thrombocytopenia during prophylactic anticoagulation therapy. Journal of Infection and Chemotherapy, 2022, , .	0.8	3
9	Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication. Journal of Medical Virology, 2022, 94, 5007-5014.	2.5	1
10	Switching to tenofovir alafenamide for nucleos(t)ide analogueâ€experienced patients with chronic hepatitis B: week 144 results from a realâ€world, multiâ€centre cohort study. Alimentary Pharmacology and Therapeutics, 2022, 56, 713-722.	1.9	25
11	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. Hepatology International, 2021, 15, 71-81.	1.9	14
12	The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995â€“2040. Hepatology International, 2021, 15, 366-379.	1.9	71
13	Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir. American Journal of Gastroenterology, 2021, 116, 1264-1273.	0.2	12
14	Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR. Cancers, 2021, 13, 3455.	1.7	11
15	Kyushu and Okinawa Population Study (KOPS): a large prospective cohort study in Japan. BMJ Open, 2021, 11, e053763.	0.8	2
16	Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. Journal of Infectious Diseases, 2020, 221, 389-399.	1.9	58
17	Prevalence and characteristics of occult hepatitis B virus infection in Japanese human immunodeficiency virus-infected patients. Journal of Infection and Chemotherapy, 2020, 26, 28-32.	0.8	9
18	Cure With Interferonâ€Free Directâ€Acting Antiviral Is Associated With Increased Survival in Patients With Hepatitis C Virusâ€Related Hepatocellular Carcinoma From Both East and West. Hepatology, 2020, 71, 1910-1922.	3.6	70

#	Article	IF	Citations
19	Ledipasvir and sofosbuvir for 12Âweeks for hepatitisÂC virus genotypeÂ2 infection: A propensity score matched analysis. Hepatology Research, 2020, 50, 174-181.	1.8	8
20	Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. American Journal of Gastroenterology, 2020, 115, 271-280.	0.2	72
21	Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice Implication. Clinical Infectious Diseases, 2020, 71, 2840-2848.	2.9	30
22	Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination. Alimentary Pharmacology and Therapeutics, 2020, 52, 866-876.	1.9	20
23	Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C. Cancers, 2020, 12, 2602.	1.7	9
24	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. Hepatology International, 2020, 14, 1023-1033.	1.9	38
25	Hepatitis B Virus Reactivation Potentiated by Biologics. Infectious Disease Clinics of North America, 2020, 34, 341-358.	1.9	22
26	Development of Hepatocellular Carcinoma in Patients Aged 75â€“84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals. Journal of Infectious Diseases, 2020, , .	1.9	8
27	Diagnosis Rates of Chronic Hepatitis B in Privately Insured Patients in the United States. JAMA Network Open, 2020, 3, e201844.	2.8	42
28	Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Liver International, 2020, 40, 1578-1589.	1.9	38
29	Editorial: FAST scoreâ€•a new predictive marker for HCC after SVRâ€”author's reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 1224-1224.	1.9	1
30	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium. Hepatology International, 2019, 13, 587-598.	1.9	27
31	Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan. BMJ Open, 2019, 9, e023405.	0.8	0
32	Toxocariasis Suspected of Having Infiltrated Directly from the Liver to the Lung through the Diaphragm. Internal Medicine, 2019, 58, 2737-2741.	0.3	5
33	Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis. Journal of Hepatology, 2019, 71, 473-485.	1.8	62
34	Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999â€“2019: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2019, 4, 389-398.	3.7	616
35	Glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C genotype 1 or 2 infection: Results from a multicenter, realâ€•world cohort study. Hepatology Research, 2019, 49, 617-626.	1.8	36
36	Systematic review with metaâ€•analysis: effectiveness and tolerability of interferonâ€•free directâ€•acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia. Alimentary Pharmacology and Therapeutics, 2018, 47, 550-562.	1.9	52

#	Article	IF	Citations
37	Potential risk of <scp>HBV</scp> reactivation in patients with resolved <scp>HBV</scp> infection undergoing directâ€acting antiviral treatment for <scp>HCV</scp>. Liver International, 2018, 38, 76-83.	1.9	37
38	Shortâ€term risk of hepatocellular carcinoma after hepatitis C virus eradication following directâ€acting antiâ€viral treatment. Alimentary Pharmacology and Therapeutics, 2018, 47, 104-113.	1.9	94
39	Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis. BMJ Open Gastroenterology, 2018, 5, e000207.	1.1	11
40	Elbasvir plus grazoprevir for patients with chronic hepatitis C genotype 1: A multicenter, real-world cohort study focusing on chronic kidney disease. Antiviral Research, 2018, 159, 143-152.	1.9	24
41	Sustained virologic response (SVR) to direct-acting antiviral (DAA) therapy in patients with chronic hepatitis C virus (HCV) infection and hepatocellular carcinoma (HCC): a systematic review and meta-analysis. Journal of Hepatology, 2018, 68, S259-S260.	1.8	0
42	Validation of AASLD treatment guideline eligibility based on disease outcomes of large community and clinical cohorts of chronic hepatitis B patients. Journal of Hepatology, 2018, 68, S503.	1.8	0
43	Efficacy and safety of direct-acting antivirals for 1,961 Japanese chronic hepatitis C patients â€“ Real Word Data from a multicenter cohort. Journal of Hepatology, 2018, 68, S286.	1.8	0
44	Validation of a clinical scoring system to predict risk of hepatocellular carcinoma in an ethnically diverse cohort of patients with chronic hepatitis C virus infection. Journal of Hepatology, 2018, 68, S305-S306.	1.8	0
45	Secondary Syphilis with Pulmonary Involvement. Internal Medicine, 2018, 57, 121-126.	0.3	19
46	Estimated the number of undiagnosed patients and antiviral treatment rate of chronic hepatitis B in the U.S. based on the Truven Health MarketScan Database. Journal of Hepatology, 2018, 68, S481-S482.	1.8	0
47	Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia. BMJ Open Gastroenterology, 2018, 5, e000209.	1.1	13
48	Development of hepatocellular carcinoma following HCV eradication by direct-acting antivirals: Real-life experience from Japanese multicenter cohort. Journal of Hepatology, 2018, 68, S549-S550.	1.8	0
49	Comparison of the Abbott RealTime HCV and Roche COBAS Ampliprep/COBAS TaqMan HCV Assays for the Monitoring of Sofosbuvir-Based Therapy. Antiviral Therapy, 2017, 22, 61-70.	0.6	8
50	Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75Âyears and over with or without cirrhosis. Hepatology Research, 2017, 47, E120-E131.	1.8	32
51	NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. Journal of Gastroenterology, 2017, 52, 845-854.	2.3	46
52	A case of amebiasis with negative serologic markers that caused intra-abdominal abscess. Journal of Infection and Chemotherapy, 2017, 23, 778-781.	0.8	0
53	Factors that influence the improvement of serum albumin during interferon-free sofosbuvir/ledipasvir therapy for Japanese patients with chronic hepatitis C virus infection. Journal of Hepatology, 2017, 66, S280-S281.	1.8	0
54	Effectiveness and safety of sofosbuvir-based regimens for Japanese patients with hepatitis C virus genotype 1b or 2 infection: real life experience from a multicenter cohort. Journal of Hepatology, 2017, 66, S308.	1.8	0

#	Article	IF	Citations
55	The Expression Level of Neutrophil CD64 Is a Useful Marker of Systemic Inflammation Associated with HIV Infection. AIDS Research and Human Retroviruses, 2017, 33, 147-156.	0.5	10
56	Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy. Drug Design, Development and Therapy, 2017, Volume 11, 3197-3204.	2.0	24
57	Efficacy of interferonâ€beta plus ribavirin combination treatment on the development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C. Hepatology Research, 2016, 46, E174-80.	1.8	4
58	Rapid Decrease of the Non-Invasive Serum Liver Fibrosis Marker WFA+-M2BP by IFN-Free Therapy. Journal of Hepatology, 2016, 64, S726-S727.	1.8	0
59	Effectiveness and Safety of Sofosbuvir and Ribavirin for Elderly Patients with HCV Genotype 2 Infection. Journal of Hepatology, 2016, 64, S759-S760.	1.8	0
60	The Safety and Efficacy of Direct-Acting Antiviral Treatment for Patients with Genotype 1 Chronic Hepatitis C and Renal Impairment. Journal of Hepatology, 2016, 64, S801-S802.	1.8	1
61	Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis. Antiviral Research, 2016, 136, 37-44.	1.9	41
62	The relation of postprandial plasma glucose and serum endostatin to the urinary albumin excretion of residents with prediabetes: results from the Kyushu and Okinawa Population Study (KOPS). International Urology and Nephrology, 2016, 48, 851-857.	0.6	3
63	Influence of insulin resistance on the development of hepatocellular carcinoma after antiviral treatment for non-cirrhotic patients with chronic hepatitis C. Infectious Agents and Cancer, 2016, 11, 9.	1.2	3
64	Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trial. Diabetology and Metabolic Syndrome, 2016, 8, 15.	1.2	11
65	Association of IL28B rs8099917 genotype and female sex with spontaneous clearance of hepatitis C virus infection: a Japanese cross-sectional study. Archives of Virology, 2016, 161, 641-648.	0.9	11
66	Serum <scp>WFA</scp>⁺â€M2<scp>BP</scp> is a nonâ€invasive liver fibrosis marker that can predict the efficacy of directâ€acting antiâ€viralâ€based triple therapy for chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 2016, 43, 114-124.	1.9	44
67	Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy. Antiviral Research, 2016, 126, 35-42.	1.9	4
68	Non-Invasive Fibrosis Assessment Predicts Sustained Virological Response to Telaprevir with Pegylated Interferon and Ribavirin for Chronic Hepatitis C. Antiviral Therapy, 2015, 20, 185-192.	0.6	8
69	P0833 : Simeprevir- and telaprevir-based triple therapies for genotype 1b chronic hepatitis C patients aged 70 and over in a multicentre cohort study. Journal of Hepatology, 2015, 62, S649.	1.8	0
70	P0845 : Comparative study on the effectiveness of simeprevir or telaprevir in combination with peginterferon and ribavirin for chronic HCV genotype 1b infection. Journal of Hepatology, 2015, 62, S655-S656.	1.8	0
71	A case of granulomatosis with polyangiitis preceded by subacute thyroiditis. Clinical Case Reports (discontinued), 2015, 3, 139-144.	0.2	0
72	Bacterial Infection as an Adverse Effect of Telaprevir-based Triple Therapy for Chronic Hepatitis C Infection. Internal Medicine, 2015, 54, 567-572.	0.3	4

#	Article	IF	Citations
73	Comparative safety study on severe anemia by simeprevir versus telaprevirâ€based triple therapy for chronic hepatitis <scp>C</scp>. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1309-1316.	1.4	10
74	Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for nonâ€cirrhotic patients with chronic hepatitis C virus genotype 1b infection. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1759-1767.	1.4	11
75	Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure. Journal of Viral Hepatitis, 2015, 22, 992-1001.	1.0	6
76	The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients. Journal of Infection and Chemotherapy, 2015, 21, 264-271.	0.8	5
77	Subclinical carotid atherosclerosis predicts the incidence of chronic kidney disease in a Japanese general population. Atherosclerosis, 2015, 241, e64-e65.	0.4	0
78	Raloxifene improves arterial stiffness and the carotid IMT progression in postmenopausal osteopenia/osteoporosis women over 12 months. Atherosclerosis, 2015, 241, e145.	0.4	0
79	Subclinical carotid atherosclerosis and triglycerides predict the incidence of chronic kidney disease in the Japanese general population: Results from the Kyushu and Okinawa Population Study (KOPS). Atherosclerosis, 2015, 238, 207-212.	0.4	33
80	Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients. World Journal of Gastroenterology, 2015, 21, 4696-4706.	1.4	4
81	Predictors of kidney tubular dysfunction induced by adefovir treatment for chronic hepatitis B. World Journal of Gastroenterology, 2015, 21, 2116-2123.	1.4	25
82	Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C. World Journal of Hepatology, 2015, 7, 2688.	0.8	0
83	The utility of urinary myo-inositol as a marker of glucose intolerance. Diabetes Research and Clinical Practice, 2014, 103, 88-96.	1.1	14
84	Influence of low-density lipoprotein cholesterol on virological response to telaprevir-based triple therapy for chronic HCV genotype 1b infection. Antiviral Research, 2014, 104, 102-109.	1.9	10
85	Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir-based triple therapy is useful for predicting virological response. Journal of Antimicrobial Chemotherapy, 2014, 69, 483-490.	1.3	17
86	Nocturnal Difference in Ultra-Low Frequency Band of the Heart Rate Variability of Patients Stratified by Kampo Medicine Prescription. Journal of Alternative and Complementary Medicine, 2014, 20, A91-A91.	2.1	0
87	A case of successful treatment with telaprevir-based triple therapy for hepatitis C infection after treatment failure with vaniprevir-based triple therapy. Journal of Infection and Chemotherapy, 2014, 20, 577-581.	0.8	5
88	A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-l± and ribavirin therapy. Journal of Infection and Chemotherapy, 2014, 20, 320-324.	0.8	4
89	Efficacy and safety of splenectomy in telaprevirâ€based triple therapy for chronic hepatitis <scp>C</scp> patients with thrombocytopenia and advanced fibrosis. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 1728-1735.	1.4	3
90	P1170 VIROLOGICAL RESPONSE AT WEEK 6 OF TELAPREVIR-BASED TRIPLE THERAPY IS THE MOST EFFECTIVE PREDICTOR OF CHRONIC HEPATITIS C TREATMENT OUTCOME. Journal of Hepatology, 2014, 60, S474.	1.8	0

#	Article	IF	Citations
91	P1103 IMPACT OF THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL ON RESPONSE TO TELAPREVIR-BASED TRIPLE THERAPY FOR CHRONIC HEPATITIS C PATIENTS. Journal of Hepatology, 2014, 60, S445-S446.	1.8	0
92	P1108 EFFICACY AND TOLERABILITY OF TELAPREVIR-BASED TRIPLE THERAPY FOR ADVANCED FIBROSIS STAGE CHRONIC HEPATITIS C PATIENTS: RESULTS OF THE KYUSHU UNIVERSITY LIVER DISEASE STUDY GROUP. Journal of Hepatology, 2014, 60, S447.	1.8	0
93	Hepatitis B Virus-related Immune Reconstitution Inflammatory Syndrome in Two Patients Coinfected with Human Immunodeficiency Virus Diagnosed with a Liver Biopsy. Internal Medicine, 2014, 53, 2165-2170.	0.3	14
94	Nocturnal Difference in the Ultra Low Frequency Band of Heart Rate Variability in Patients Stratified by Kampo Medicine Prescription. Circulation Journal, 2014, 78, 1924-1927.	0.7	6
95	The serum undercarboxylated osteocalcin level and the diet of a Japanese population: results from the Kyushu and Okinawa Population Study (KOPS). Endocrine, 2013, 43, 635-642.	1.1	14
96	Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. Journal of Hepatology, 2013, 59, 205-212.	1.8	69
97	Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: A prospective, multicenter study. Journal of Hepatology, 2013, 58, 495-501.	1.8	126
98	Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy. Journal of Hepatology, 2013, 59, 667-674.	1.8	49
99	Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. Alimentary Pharmacology and Therapeutics, 2013, 38, 1076-1085.	1.9	23
100	Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: A comparison of two real-time PCR assays. Antiviral Research, 2013, 99, 119-124.	1.9	23
101	A case report of human immunodeficiency virus-associated anaplastic lymphoma kinase protein-negative anaplastic large cell lymphoma. SpringerPlus, 2013, 2, 400.	1.2	3
102	Reply to: â€œLower incidence of hepatocellular carcinoma in patients with transient virologic response to peginterferon and ribavirin combination therapy: Is it really the effect of the therapy?â€• Journal of Hepatology, 2013, 58, 839-840.	1.8	0
103	886 IMPACT OF THE VIRAL KINETICS OF CHRONIC HEPATITIS C PATIENTS TREATED WITH TELAPREVIR IN COMBINATION WITH PEGYLATED INTERFERON a2b AND RIBAVIRIN. Journal of Hepatology, 2013, 58, S365.	1.8	1
104	820 THERAPEUTIC DRUG MONITORING OF TELAPREVIR IN CHRONIC HEPATITIS C PATIENTS RECEIVING TELAPREVIR-BASED TRIPLE THERAPY IS USEFUL FOR PREDICTING VIROLOGICAL RESPONSE AND AVOIDING TOXIC DRUG-EXPOSURE. Journal of Hepatology, 2013, 58, S336.	1.8	3
105	Association between chronic hepatitis C virus infection and high levels of circulating N-terminal pro-brain natriuretic peptide. Endocrine, 2013, 43, 200-205.	1.1	3
106	Interferon-Î±-Induced Changes to Natural Killer Cells Are Associated with the Treatment Outcomes in Patients with HCV Infections. Hepatitis Research and Treatment, 2013, 2013, 1-7.	2.0	2
107	Valuable antiviral therapeutic options for the treatment of chronic hepatitis C patients with thrombocytopenia. Journal of Viral Hepatitis, 2013, 20, 838-846.	1.0	2
108	Commentary: triple therapy for patients with chronic hepatitis C and advanced fibrosis? Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2013, 38, 1408-1408.	1.9	7

#	Article	IF	Citations
109	A case of Fanconi's syndrome caused by long-term administration of adefovir by a patient with chronic hepatitis B. Acta Hepatologica Japonica, 2013, 54, 187-193.	0.0	6
110	Pre-treatment role of inosine triphosphate pyrophosphatase polymorphism for predicting anemia in Egyptian hepatitis C virus patients. World Journal of Gastroenterology, 2013, 19, 1387.	1.4	21
111	Tongue Color as an Indicator of Gastroesophageal Disease. American Journal of Gastroenterology, 2013, 108, S598.	0.2	0
112	An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Journal of Infection and Chemotherapy, 2012, 18, 689-697.	0.8	4
113	Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: A randomized trial. Journal of Hepatology, 2012, 57, 1186-1192.	1.8	52
114	Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1. Journal of Hepatology, 2012, 57, 534-540.	1.8	37
115	1197 INSULIN RESISTANCE UNDERMINES THE ADVANTAGES OF IL28B POLYMORPHISM IN THE PEGYLATED INTERFERON a2B AND RIBAVIRIN TREATMENT FOR CHRONIC HEPATITIS C PATIENTS WITH GENOTYPE 1. Journal of Hepatology, 2012, 56, S474-S475.	1.8	1
116	1112RALOXIFENE HYDROCHLORIDE AS A NOVEL ANTIVIRAL AGENT: INHIBITION OF HEPATITIS C VIRUS (HCV) REPLICATION. Journal of Hepatology, 2012, 56, S438.	1.8	0
117	1144 COMPLETE HEPATITIS C VIRUS ELIMINATION DURING PEGYLATED INTERFERON a2B AND RIBAVIRIN TREATMENT REDUCES THE RISK OF PROGRESSION TO HEPATOCELLULAR CARCINOMA. Journal of Hepatology, 2012, 56, S452.	1.8	2
118	Evaluation of the adverse effect of premature discontinuation of pegylated interferon Î±â€2b and ribavirin treatment for chronic hepatitis C virus infection: Results from Kyushu University Liver Disease Study. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1233-1240.	1.4	34
119	The effect of gastric inhibitory polypeptide on intestinal glucose absorption and intestinal motility in mice. Biochemical and Biophysical Research Communications, 2011, 404, 115-120.	1.0	27
120	Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog. Hepatology Research, 2011, 41, 1178-1188.	1.8	55
121	Abbott RealTime PCR assay is useful for evaluating virological response to antiviral treatment for chronic hepatitis C. Journal of Infection and Chemotherapy, 2011, 17, 737-743.	0.8	4
122	Ribavirin concentration in the later stages of 48 week pegylated interferon-Â2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response. Journal of Antimicrobial Chemotherapy, 2011, 66, 1127-1139.	1.3	20
123	Long-term effects of lamivudine treatment in Japanese chronic hepatitis B patients. World Journal of Gastroenterology, 2011, 17, 2945.	1.4	5
124	Treatment for Eradication of Helicobacter pylori Infection among Chronic Hepatitis C Patients. Gut and Liver, 2011, 5, 447-453.	1.4	8
125	Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment. BMC Gastroenterology, 2010, 10, 38.	0.8	10
126	The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Research, 2009, 83, 127-134.	1.9	123

#	Article	IF	Citations
127	Protein-losing enteropathy during highly active antiretroviral therapy in a patient with AIDS-related disseminated Mycobacterial avium complex infection. Journal of Infection and Chemotherapy, 2009, 15, 252-256.	0.8	10
128	Oral and Poster Papers Submitted for Presentation at the 5th Congress of the EUGMS â€œGeriatric Medicine in a Time of Generational Shift September 3â€“6, 2008 Copenhagen, Denmark. Journal of Nutrition, Health and Aging, 2008, 12, 545-593.	1.5	0
129	Intravenous immunoglobulin therapy for severe arthritis associated with human parvovirus B19 infection. Journal of Infection and Chemotherapy, 2008, 14, 377-382.	0.8	26
130	å½“é™¢ã«ãŠã'ã‚‹ãƒãƒ³ã‚³ãƒžã‚·ãƒ³è€æ€§è…¸çƒèŒã®é™¢å†…ä¼æ'ä º‹ä¾‹. Japanese Journal of Environmental Infections, 2008, 23, 3	0.1	2
131	The spontaneously diabetic Torii rat with gastroenteropathy. Diabetes Research and Clinical Practice, 2007, 75, 127-134.	1.1	18
132	Transient elastography for patients with chronic hepatitis B and C virus infection: Nonâ€invasive, quantitative assessment of liver fibrosis. Hepatology Research, 2007, 37, 1002-1010.	1.8	79
133	Targeting AMAP1 and cortactin binding bearing an atypical src homology 3/proline interface for prevention of breast cancer invasion and metastasis. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7036-7041.	3.3	100
134	Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients. British Journal of Cancer, 2004, 91, 498-503.	2.9	78